Back to Search
Start Over
Prescription-Event monitoring study on safety and efficacy of levonadifloxacin (oral and I.V.) in management of bacterial infections: Findings of real-world observational study.
- Source :
-
International Journal of Applied & Basic Medical Research . Jan-Mar2022, Vol. 12 Issue 1, p30-36. 7p. - Publication Year :
- 2022
-
Abstract
- Background: Levonadifloxacin is a novel broad-spectrum antibiotic belonging to the benzoquinolizine subclass of quinolones. It is available in intravenous as well as oral formulation for the treatment of infections caused by common Gram-positive bacterial pathogens including methicillin-resistant Staphylococcus aureus (MRSA). Patients and Methods: This study retrospectively assessed the real-world safety and efficacy of levonadifloxacin (oral and/or IV) in the treatment of 1229 patients across various clinical conditions. Study outcomes were clinical and microbiological success at the end of therapy. Results: The mean duration of levonadifloxacin therapy was 7.2 days, with a time to clinical improvement averaging at 4 days. Three hundred and three patients received oral therapy, 875 received IV, and 51 received a combination of IV followed by oral therapy. Patients were prescribed levonadifloxacin for skin and soft-tissue infections, diabetic foot infections, septicemia, catheter-related bloodstream infections, bone and joint infections, febrile neutropenia, and respiratory infections including COVID-19 pneumonia. High clinical success rates of 98.3%, 93.7%, and 96.1% with oral, IV, and IV followed by oral levonadifloxacin, respectively, were obtained. Only 11 mild adverse events were reported in 9 patients which included constipation, diarrhea, hyperglycemia, nausea, fatigue, and vomiting. Overall, 96.3% and 97.3% of investigators rated the efficacy and safety of levonadifloxacin as "good to excellent." Conclusions: An excellent safety and efficacy profile of levonadifloxacin was observed in this study making it a suitable treatment option for management of various bacterial infections, including those caused by resistant Gram-positive pathogens such as MRSA and quinolone-resistant S. aureus. [ABSTRACT FROM AUTHOR]
Details
- Language :
- English
- ISSN :
- 2229516X
- Volume :
- 12
- Issue :
- 1
- Database :
- Academic Search Index
- Journal :
- International Journal of Applied & Basic Medical Research
- Publication Type :
- Academic Journal
- Accession number :
- 155081390
- Full Text :
- https://doi.org/10.4103/ijabmr.ijabmr_602_21